Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer

Federico Carbone, Francesco Grossi, Aldo Bonaventura, Alessandra Vecchié, Silvia Minetti, Nicholas Bardi, Edoardo Elia, Anna Maria Ansaldo, Daniele Ferrara, Erika Rijavec, Maria Giovanna Dal Bello, Federica Biello, Giovanni Rossi, Marco Tagliamento, Angela Alama, Simona Coco, Paolo Spallarossa, Franco Dallegri, Carlo Genova, Fabrizio Montecucco

Research output: Contribution to journalArticle

Abstract

Treatment with nivolumab improves survival and response rate in non-small cell lung cancer (NSCLC). Nevertheless, due to its high financial cost, identifying predictors of response to treatment has become an urgent need. Here, we focused on serum osteopontin (OPN), a pleiotropic protein overexpressed in lung cancer and involved in the immune response. A cohort of NSCLC patients (n = 72) treated with nivolumab was enrolled. Blood samples were collected at the time of first five nivolumab administrations. OPN and high-sensitivity C-reactive protein (hs-CRP) were assayed at each time point. The primary endpoint was to assess the predictive value of baseline serum levels of OPN towards overall survival (OS). Secondary endpoints included the potential association between OPN, hs-CRP and response to nivolumab. OPN and hs-CRP correlate with each other, with neutrophil count and biochemical markers of metastatic disease. At baseline, serum OPN increased with increasing Eastern Cooperative Oncology Group scale of Performance Status (ECOG PS). When Eastern Cooperative Oncology Group scale of Performance Status) (RECIST) criteria were considered, high baseline OPN levels were associated with a worse response to nivolumab. Cox hazard regression further confirmed baseline serum OPN as a predictor of mortality with the best predictive accuracy for serum levels above 37.7 ng/mL. Patients above the cut-off value had a higher mortality rate as compared to low serum OPN levels during follow up. Serum OPN may have a predictive role in NSCLC patients treated with nivolumab. Although larger confirmatory studies are needed, measuring serum OPN levels at baseline can be a clinically useful tool in a near future.

Original languageEnglish
Pages (from-to)449-456
Number of pages8
JournalClinical and Experimental Metastasis
Volume36
Issue number5
DOIs
Publication statusPublished - Oct 15 2019

Fingerprint

Osteopontin
Non-Small Cell Lung Carcinoma
Serum
Therapeutics
C-Reactive Protein
nivolumab
Mortality
Lung Neoplasms
Neutrophils
Survival Rate
Biomarkers

Keywords

  • Inflammation
  • Neutrophil
  • Nivolumab
  • Non-small cell lung cancer
  • Osteopontin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer. / Carbone, Federico; Grossi, Francesco; Bonaventura, Aldo; Vecchié, Alessandra; Minetti, Silvia; Bardi, Nicholas; Elia, Edoardo; Ansaldo, Anna Maria; Ferrara, Daniele; Rijavec, Erika; Dal Bello, Maria Giovanna; Biello, Federica; Rossi, Giovanni; Tagliamento, Marco; Alama, Angela; Coco, Simona; Spallarossa, Paolo; Dallegri, Franco; Genova, Carlo; Montecucco, Fabrizio.

In: Clinical and Experimental Metastasis, Vol. 36, No. 5, 15.10.2019, p. 449-456.

Research output: Contribution to journalArticle

Carbone, F, Grossi, F, Bonaventura, A, Vecchié, A, Minetti, S, Bardi, N, Elia, E, Ansaldo, AM, Ferrara, D, Rijavec, E, Dal Bello, MG, Biello, F, Rossi, G, Tagliamento, M, Alama, A, Coco, S, Spallarossa, P, Dallegri, F, Genova, C & Montecucco, F 2019, 'Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer', Clinical and Experimental Metastasis, vol. 36, no. 5, pp. 449-456. https://doi.org/10.1007/s10585-019-09984-z
Carbone, Federico ; Grossi, Francesco ; Bonaventura, Aldo ; Vecchié, Alessandra ; Minetti, Silvia ; Bardi, Nicholas ; Elia, Edoardo ; Ansaldo, Anna Maria ; Ferrara, Daniele ; Rijavec, Erika ; Dal Bello, Maria Giovanna ; Biello, Federica ; Rossi, Giovanni ; Tagliamento, Marco ; Alama, Angela ; Coco, Simona ; Spallarossa, Paolo ; Dallegri, Franco ; Genova, Carlo ; Montecucco, Fabrizio. / Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer. In: Clinical and Experimental Metastasis. 2019 ; Vol. 36, No. 5. pp. 449-456.
@article{c4c813e04b044cb097e21355200569b0,
title = "Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer",
abstract = "Treatment with nivolumab improves survival and response rate in non-small cell lung cancer (NSCLC). Nevertheless, due to its high financial cost, identifying predictors of response to treatment has become an urgent need. Here, we focused on serum osteopontin (OPN), a pleiotropic protein overexpressed in lung cancer and involved in the immune response. A cohort of NSCLC patients (n = 72) treated with nivolumab was enrolled. Blood samples were collected at the time of first five nivolumab administrations. OPN and high-sensitivity C-reactive protein (hs-CRP) were assayed at each time point. The primary endpoint was to assess the predictive value of baseline serum levels of OPN towards overall survival (OS). Secondary endpoints included the potential association between OPN, hs-CRP and response to nivolumab. OPN and hs-CRP correlate with each other, with neutrophil count and biochemical markers of metastatic disease. At baseline, serum OPN increased with increasing Eastern Cooperative Oncology Group scale of Performance Status (ECOG PS). When Eastern Cooperative Oncology Group scale of Performance Status) (RECIST) criteria were considered, high baseline OPN levels were associated with a worse response to nivolumab. Cox hazard regression further confirmed baseline serum OPN as a predictor of mortality with the best predictive accuracy for serum levels above 37.7 ng/mL. Patients above the cut-off value had a higher mortality rate as compared to low serum OPN levels during follow up. Serum OPN may have a predictive role in NSCLC patients treated with nivolumab. Although larger confirmatory studies are needed, measuring serum OPN levels at baseline can be a clinically useful tool in a near future.",
keywords = "Inflammation, Neutrophil, Nivolumab, Non-small cell lung cancer, Osteopontin",
author = "Federico Carbone and Francesco Grossi and Aldo Bonaventura and Alessandra Vecchi{\'e} and Silvia Minetti and Nicholas Bardi and Edoardo Elia and Ansaldo, {Anna Maria} and Daniele Ferrara and Erika Rijavec and {Dal Bello}, {Maria Giovanna} and Federica Biello and Giovanni Rossi and Marco Tagliamento and Angela Alama and Simona Coco and Paolo Spallarossa and Franco Dallegri and Carlo Genova and Fabrizio Montecucco",
year = "2019",
month = "10",
day = "15",
doi = "10.1007/s10585-019-09984-z",
language = "English",
volume = "36",
pages = "449--456",
journal = "Clinical and Experimental Metastasis",
issn = "0262-0898",
publisher = "Springer Netherlands",
number = "5",

}

TY - JOUR

T1 - Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer

AU - Carbone, Federico

AU - Grossi, Francesco

AU - Bonaventura, Aldo

AU - Vecchié, Alessandra

AU - Minetti, Silvia

AU - Bardi, Nicholas

AU - Elia, Edoardo

AU - Ansaldo, Anna Maria

AU - Ferrara, Daniele

AU - Rijavec, Erika

AU - Dal Bello, Maria Giovanna

AU - Biello, Federica

AU - Rossi, Giovanni

AU - Tagliamento, Marco

AU - Alama, Angela

AU - Coco, Simona

AU - Spallarossa, Paolo

AU - Dallegri, Franco

AU - Genova, Carlo

AU - Montecucco, Fabrizio

PY - 2019/10/15

Y1 - 2019/10/15

N2 - Treatment with nivolumab improves survival and response rate in non-small cell lung cancer (NSCLC). Nevertheless, due to its high financial cost, identifying predictors of response to treatment has become an urgent need. Here, we focused on serum osteopontin (OPN), a pleiotropic protein overexpressed in lung cancer and involved in the immune response. A cohort of NSCLC patients (n = 72) treated with nivolumab was enrolled. Blood samples were collected at the time of first five nivolumab administrations. OPN and high-sensitivity C-reactive protein (hs-CRP) were assayed at each time point. The primary endpoint was to assess the predictive value of baseline serum levels of OPN towards overall survival (OS). Secondary endpoints included the potential association between OPN, hs-CRP and response to nivolumab. OPN and hs-CRP correlate with each other, with neutrophil count and biochemical markers of metastatic disease. At baseline, serum OPN increased with increasing Eastern Cooperative Oncology Group scale of Performance Status (ECOG PS). When Eastern Cooperative Oncology Group scale of Performance Status) (RECIST) criteria were considered, high baseline OPN levels were associated with a worse response to nivolumab. Cox hazard regression further confirmed baseline serum OPN as a predictor of mortality with the best predictive accuracy for serum levels above 37.7 ng/mL. Patients above the cut-off value had a higher mortality rate as compared to low serum OPN levels during follow up. Serum OPN may have a predictive role in NSCLC patients treated with nivolumab. Although larger confirmatory studies are needed, measuring serum OPN levels at baseline can be a clinically useful tool in a near future.

AB - Treatment with nivolumab improves survival and response rate in non-small cell lung cancer (NSCLC). Nevertheless, due to its high financial cost, identifying predictors of response to treatment has become an urgent need. Here, we focused on serum osteopontin (OPN), a pleiotropic protein overexpressed in lung cancer and involved in the immune response. A cohort of NSCLC patients (n = 72) treated with nivolumab was enrolled. Blood samples were collected at the time of first five nivolumab administrations. OPN and high-sensitivity C-reactive protein (hs-CRP) were assayed at each time point. The primary endpoint was to assess the predictive value of baseline serum levels of OPN towards overall survival (OS). Secondary endpoints included the potential association between OPN, hs-CRP and response to nivolumab. OPN and hs-CRP correlate with each other, with neutrophil count and biochemical markers of metastatic disease. At baseline, serum OPN increased with increasing Eastern Cooperative Oncology Group scale of Performance Status (ECOG PS). When Eastern Cooperative Oncology Group scale of Performance Status) (RECIST) criteria were considered, high baseline OPN levels were associated with a worse response to nivolumab. Cox hazard regression further confirmed baseline serum OPN as a predictor of mortality with the best predictive accuracy for serum levels above 37.7 ng/mL. Patients above the cut-off value had a higher mortality rate as compared to low serum OPN levels during follow up. Serum OPN may have a predictive role in NSCLC patients treated with nivolumab. Although larger confirmatory studies are needed, measuring serum OPN levels at baseline can be a clinically useful tool in a near future.

KW - Inflammation

KW - Neutrophil

KW - Nivolumab

KW - Non-small cell lung cancer

KW - Osteopontin

UR - http://www.scopus.com/inward/record.url?scp=85071714126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071714126&partnerID=8YFLogxK

U2 - 10.1007/s10585-019-09984-z

DO - 10.1007/s10585-019-09984-z

M3 - Article

C2 - 31376097

AN - SCOPUS:85071714126

VL - 36

SP - 449

EP - 456

JO - Clinical and Experimental Metastasis

JF - Clinical and Experimental Metastasis

SN - 0262-0898

IS - 5

ER -